Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Autolus Therapeutics plc (Nasdaq: AUTL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a commercial-stage biopharmaceutical issuer. Autolus is incorporated in England and Wales, and its American Depositary Shares trade on The Nasdaq Global Select Market. As a foreign private issuer, Autolus files reports and current disclosures with the U.S. Securities and Exchange Commission, including Forms 20-F and 6-K, as well as current reports on Form 8-K related to material events.
In its filings, Autolus provides information on its business of developing, manufacturing and delivering next-generation programmed T cell therapies for cancer and autoimmune disease. Investors can use these documents to follow the commercial launch and performance of AUCATZYL® (obecabtagene autoleucel; obe-cel), a CD19-directed genetically modified autologous T cell immunotherapy indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Filings often reference net product revenue, cost of sales, research and development expenses, and selling, general and administrative expenses, as well as cash, cash equivalents and marketable securities.
Current reports on Form 8-K for Autolus have included quarterly financial results, corporate updates, and governance changes such as the appointment of a principal accounting officer. These documents can also incorporate press releases that discuss clinical trial progress in programs like CATULUS, CARLYSLE, LUMINA, BOBCAT and ALARIC, and provide context on how Autolus is advancing its pipeline across hematological malignancies, solid tumors and autoimmune diseases.
On Stock Titan, SEC filings for AUTL are updated in near real time from EDGAR. Integrated AI-powered summaries help explain the key points in lengthy filings, including annual reports, interim financial updates and material event disclosures. Users can quickly scan for information on Autolus’ T cell programming technologies, AUCATZYL commercialization, manufacturing initiatives and capital position without reading every line of the underlying documents.
Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on next‑generation programmed T cell therapies for cancer and autoimmune diseases. Its lead product, AUCATZYL (obe-cel), a CD19 CAR T therapy, is approved for adult relapsed or refractory B‑cell precursor acute lymphoblastic leukemia in the US, U.K. and EU.
Commercial launch and first US sales began in January 2025, with a U.K. launch through the National Health Service in January 2026. EU marketing authorization has been granted, but launch there is on hold while pricing and market feasibility are evaluated, and no EU sales are expected in 2026.
The company is expanding obe‑cel into pediatric B‑ALL and B‑NHL, additional B‑cell malignancies and autoimmune indications including systemic lupus erythematosus, lupus nephritis and progressive multiple sclerosis. Autolus operates a purpose‑built manufacturing facility in Stevenage, U.K., designed to support global CAR T supply using a semi‑automated, closed manufacturing platform.
Autolus Therapeutics reported fourth-quarter and full-year 2025 results that reflect its first commercial year for AUCATZYL. Net product revenue reached $23.3 million in Q4 2025 and $74.3 million for the full year, driving total 2025 revenue to $75.4 million including license revenue.
Autolus projects 2026 AUCATZYL net product revenue of $120 million to $135 million and expects to achieve a shift to positive gross margin in 2026 as volumes rise and manufacturing efficiency improves. Cost of sales were $96.4 million in 2025, research and development expenses $117.7 million, and selling, general and administrative expenses $131.9 million, resulting in a full-year net loss of $287.5 million.
Cash, cash equivalents and marketable securities totaled $300.7 million as of December 31, 2025, down from $588.0 million a year earlier, and the company expects this funding, together with anticipated AUCATZYL revenue, to support operations into Q4 2027. Autolus also highlighted advancing trials of obe-cel in pediatric B-ALL, lupus nephritis, progressive multiple sclerosis and systemic lupus erythematosus with multiple data readouts expected between year-end 2026 and 2028.
Autolus Therapeutics plc director Ryan Richardson reported an initial holding of a share option covering 80,000 underlying American Depositary Shares. The option has an exercise price of $1.41 per share and expires on December 1, 2035. It vests in 36 equal monthly installments starting on January 1, 2026, meaning the right to buy the shares builds gradually over three years. This filing does not reflect a new stock purchase or sale, but discloses an existing equity award position.
Autolus Therapeutics plc executive Cintia Piccina, U.S. CCO & Country General Manager, has filed a Form 3 reporting her existing equity awards. She holds share options over 500,000 American Depositary Shares at an exercise price of $1.49 expiring on October 8, 2035, and options over 148,000 ADS at $1.62 expiring on March 4, 2036. She also holds restricted share units covering 80,000 ADS that vest in four equal annual installments starting on September 1, 2026, and 33,000 RSUs vesting in four equal annual installments starting on March 4, 2027, with each RSU representing one ADS.
Autolus Therapeutics plc director Cynthia M. Butitta filed an initial ownership report showing her equity position in the company. She directly holds 10,000 American Depositary Shares, each convertible into one Ordinary Share, and a series of share options over additional American Depositary Shares with exercise prices ranging from $2.38 to $30.24 and expirations extending through 2035.
Autolus Therapeutics plc director Elisabeth Leiderman filed an initial Form 3 reporting her holdings of three option awards over American Depositary Shares. Each option covers 80,000 underlying ADS, with exercise prices of $5.5000, $3.4800 and $2.3200, expiring between December 20, 2033 and June 26, 2035. One grant is fully vested and exercisable, while the others vest in equal monthly installments beginning January 20, 2024 and July 26, 2025.
Autolus Therapeutics plc Chief Development Officer Will Matthias filed an initial ownership report showing equity awards linked to American Depositary Shares. He holds multiple share options with exercise prices of $3.63, $1.89, and $1.46 expiring between 2034 and 2036, plus restricted share units that vest in four equal annual installments starting on January 26, 2027. Each RSU represents a contingent right to receive one American Depositary Share.
Autolus Therapeutics plc director William D. Young has reported his derivative holdings in a Form 3 filing, showing options over American Depositary Shares. The disclosure lists several share option awards with exercise prices between $2.32 and $5.56 per ADS and expirations from November 2031 through June 2035. The filing notes that some options are fully vested and exercisable, while another grant vests in twelve equal monthly installments commencing on July 26, 2025. No purchases or sales of shares are reported; this filing establishes his initial reported ownership position in option awards.
Autolus Therapeutics plc director Robert Azelby filed an initial ownership report showing three option awards over American Depositary Shares. Each option covers 80,000 underlying shares with exercise prices of $6.84, $3.48 and $2.32, expiring in 2034 and 2035.
According to the footnotes, one grant vested or vests in 36 equal monthly installments commencing on January 9, 2024, another is fully vested and exercisable, and a third vested or vests in twelve equal monthly installments commencing on July 26, 2025. All holdings are reported as direct ownership.
Autolus Therapeutics plc director Rao Madduri Ravin filed an initial Form 3 reporting existing stock option holdings linked to American Depositary Shares. He holds three direct option positions, each covering 80,000 ADS, with exercise prices of $5.68, $3.48, and $2.32 per share and expirations in 2034 and 2035. One option is fully vested and exercisable, while the others vest in equal monthly installments starting on May 1, 2024 and July 26, 2025, indicating a staged compensation structure rather than recent market trades.